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Abstract
Aims/hypothesis Multiple islet autoimmunity increases risk of diabetes, but not all individuals positive for two or more islet
autoantibodies progress to disease within a decade. Major islet autoantibodies recognise insulin (IAA), GAD (GADA), islet
antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A). Here we describe the baseline characteristics of a unique cohort of ‘slow
progressors’ (n = 132) who were positive for multiple islet autoantibodies (IAA, GADA, IA-2A or ZnT8A) but did not progress
to diabetes within 10 years.
Methods Individuals were identified from five studies (BABYDIAB, Germany; Diabetes Autoimmunity Study in the Young
[DAISY], USA; All Babies in Southeast Sweden [ABIS], Sweden; Bart’s Oxford Family Study [BOX], UK and the Pittsburgh
Family Study, USA). Multiple islet autoantibody characteristics were determined using harmonised assays where possible. HLA
class II risk was compared between slow progressors and rapid progressors (n = 348 diagnosed <5 years old fromBOX) using the
χ2 test.
Results In the first available samples with detectable multiple antibodies, the most frequent autoantibodies were GADA (92%),
followed by ZnT8A (62%), IAA (59%) and IA-2A (41%). High risk HLA class II genotypes were less frequent in slow (28%)
than rapid progressors (42%, p = 0.011), but only two slow progressors carried the protective HLA DQ6 allele.
Conclusion No distinguishing characteristics of slow progressors at first detection of multiple antibodies have yet been identified.
Continued investigation of these individuals may provide insights into slow progression that will inform future efforts to slow or
prevent progression to clinical diabetes.
Keywords HLA class II . Islet autoantibodies . Slow progression . Type 1 diabetes
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Abbreviations
ABIS All Babies in Southeast Sweden
BOX Bart’s Oxford Family Study
DAISY Diabetes Autoimmunity Study in the Young
GADA Autoantibodies to GAD
IA-2A Autoantibodies to islet antigen-2
IAA Autoantibodies to insulin
ICA Islet cell antigen
mAab Multiple islet autoantibody
SNAIL Slow or Non progressive Autoimmunity to the
Islets of Langerhans
ZnT8A Autoantibodies to zinc transporter 8
Introduction
Immune-mediated destruction of pancreatic beta cells pro-
gresses at different speeds in different individuals.
Prospective birth cohort studies show that autoantibodies to
insulin (IAA), GAD (GADA), islet antigen-2 (IA-2A), and
zinc transporter 8 (ZnT8A) can be detected in children at risk
of type 1 diabetes from 6 months of age with a peak in sero-
conversion between 2 and 3 years [1]. Over 90% of individ-
uals diagnosed in childhood have at least one of these autoan-
tibodies [2]. Presence of multiple islet autoantibodies (mAabs)
is normally associated with a disease risk of 70% within
10 years [2–5], but many individuals present with clinical
symptoms later in adult life [1].
Conceptually, disease pathogenesis can be divided into
three stages: development of autoimmunity as indicated by
the presence of mAabs, defined recently as Stage 1; progres-
sion from autoimmunity to glucose intolerance (Stage 2); and
finally to overt disease (Stage 3) [6]. These stages appear to be
controlled by different genetic mechanisms, with different
HLA alleles affecting seroconversion and/or progression to
disease [7, 8]. Positivity for and/or higher levels of IAA, IA-
2A, IA-2βA and ZnT8A have also been associated with more
rapid development of hyperglycaemia [9–11].
The Slow or Non progressive Autoimmunity to the Islets of
Langerhans (SNAIL) study focuses on slow progression to
diabetes by studying a large international collection of indi-
viduals who develop islet autoimmunity (defined by presence
ofmAabs) but do not develop disease for at least 10 years. The
characteristics of humoral autoimmunity in the earliest mAab-
positive sample and the HLA class II profile in this unique
‘slow progressor’ cohort are described here. SNAIL partici-
pants derive from BABYDIAB [12], the Diabetes
Autoimmunity Study in the Young (DAISY) [13], All
Babies in Southeast Sweden (ABIS) [14], the Bart’s Oxford
(BOX) Family Study [15] and the Pittsburgh Family Study
[5]. These studies all investigated the natural history of diabe-
tes and the contribution of islet autoantibodies to disease risk.
•
•
•
•
•
•
•
•
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Three studies (BABYDIAB, DAISY and ABIS) followed
children from birth (with blood samples taken at 9 months
or 1 year), while two studies enrolled first degree relatives of
individuals with diabetes throughout life. Slow progressors
may provide new insights that inform disease prevention strat-
egies in those at risk of type 1 diabetes and help to identify
biomarkers associated with slow progression.
Methods
Participants
Slow progressors were characterised by remaining diabetes-
free for at least 10 years after mAabs (two or more of IAA,
GADA, IA-2A or ZnT8A) were first detected. As a control
group, genetic data were available for 2075 individuals diag-
nosed with type 1 diabetes under the age of 21 years and
enrolled in the BOX study. Of these, 348 were ‘rapid
progressors’ being diagnosed at less than 5 years of age and
1217 were diagnosed over 10 years of age. All individuals
were participants in existing studies approved by local ethical
review boards. Written informed consent was obtained from
participants and/or their parents/legal guardians.
Participating study cohorts
SNAIL participants were recruited from several natural histo-
ry studies, which have been described in detail elsewhere (see
electronic supplementary material [ESM] Table 1). Brief de-
scriptions of the studies are given below.
BABYDIAB, Germany BABYDIAB is a longitudinal study
examining the natural history of islet autoimmunity and
type 1 diabetes in 1650 children born to a mother or father
with type 1 diabetes [12]. Recruitment began in 1989 and
ended in 2000.
DAISY, USA DAISY has followed two cohorts of young chil-
dren at increased risk of type 1 diabetes (total n = 2547); a
cohort of relatives of individuals with type 1 diabetes (siblings
and offspring) and a newborn high genetic risk general popu-
lation cohort from the Denver area [13, 16, 17]. Recruitment
began in 1993 and ended in 2004, and follow-up is ongoing.
ABIS, SwedenAll mothers that gave birth in southeast Sweden
between October 1997 and October 1999 were invited to par-
ticipate [14]. In total 17,055 children were recruited (78.6% of
all births), of whom 7394 provided at least two samples for
autoantibody analysis.
The BOX family study, UK BOX is a longitudinal study exam-
ining risk factors for type 1 diabetes in siblings or parents
(2774 families) of a proband diagnosed under the age of 21
[15]. Autoantibodies were tested in at least one sample from
5881 relatives, diabetes-free at the time of testing. Of these,
284 have had a diabetes (any type) diagnosis. Recruitment
began in 1985 and is ongoing. All participants in SNAIL were
recruited before 2001.
The Pittsburgh Family Study, USA More than 10,000 first-
degree relatives of children and adolescents with type 1 dia-
betes (<19 years old) were recruited from the Children’s
Hospital of Pittsburgh registry and followed up from 1979
until 2015 [18]. Relatives were excluded at screening if an
OGTT or random glucose level was >7.8 mmol/l [19]. All
relatives were screened using islet cell antigen (ICA) testing.
Relatives confirmed positive for ICA were tested for IAA,
GADA and IA-2A, this included 1484 relatives recruited be-
tween 1979 and 1984.
Follow-up
Participants were followed for development of disease
through: (1) annual or semi-annual written or telephone
Table 1 Description of participants in the SNAIL study
Characteristic Overall BABY DIAB DAISY ABIS BOX Pittsburgh
n 132 22 30 11 36 33
Age at first antibody test; Median (IQR) 7 (1–18) 1 1 (1–2) 1 18 (13–38) 18 (11–33)a
Age at mAab+ sample; Median (IQR) 10 (5–20) 5 (2–5) 7 (4–10) 5 18 (13–38) 18 (11–37)
Male; n (%) 69 (54) 16 (73) 17 (57) 7 (64) 15 (42) 17 (52)
Years of follow-up since mAab+ detection; Median (IQR) 14 (12–19) 13 (11–14) 12 (1–13) 13 (13–14) 17 (14–24) 20 (13–26)
Diabetes-free at follow-up; n (%) 90 (68) 12 (55) 23 (77) 10 (100) 22 (61) 23 (70)
Genetic data available 121 22 30 10 36 23
a Earliest sample available
IQR, interquartile range; mAab+ , multiple autoantibody-positive
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contact to ascertain self-reported, clinician diagnosed diabe-
tes; (2) in ABIS, diagnosis was ascertained from the national
registration of all individuals with type 1 diabetes [11]; (3) for
BABYDIAB and willing DAISY participants, oral glucose
tolerance tests were performed at least annually and/or
HbA1c monitored [2].
Autoantibody assays
Islet autoantibodies (GADA, IA-2A, IAA and ZnT8A) were
tested in each parent study by radiobinding assays as previ-
ously described [2, 3, 11, 16, 19–21] and an overview of the
testing strategy for each study is summarised in ESM
Methods. Positivity was defined using a threshold determined
by each laboratory and where multiple samples were avail-
able, persistent autoimmunity was confirmed. Assays for
GADA and IA-2Awere calibrated against the WHO standard
in international workshops and where samples were available,
the presence of mAabs within individuals was confirmed with
harmonised assays for GADA and IA-2A [20]. Where
harmonised assays failed to confirm mAab, those individuals
were excluded.
Genetics
The HLA class II genotypeDRB1*03-DQB1*02 (DR3-DQ2)/
DRB1*04-DQB1*0302 (DR4-DQ8) (or DQB1*02 [DQ2]/
DQB1*0302 [DQ8] if DR typing was not available) was con-
sidered high risk, presence of one or two copies of DR3-DQ2
or DR4-DQ8 was considered to confer intermediate risk,
while all other genotypes or haplotypes containing
DQB1*0602 were considered low risk. HLA typing for
BOX and ABIS were carried out at the University of Bristol
[22]; other studies provided their own data [5, 13, 23].
Data analysis
Comparisons between antibody prevalence and haplotype fre-
quencies across studies and genotype frequencies between
SNAIL participants and rapid progressors were made using
χ2 tests.
Results
Overall, 132 participants were identified who remained
diabetes-free for more than 10 years after mAabs were first
detected (Table 1). After this 10-year period, participants
remained under follow-up (median 4 years, IQR 2–9 years).
During follow-up in SNAIL, 42 slow progressors were diag-
nosed with diabetes, but 90 remained diabetes-free based on
lack of self-reported disease, absence from a diabetes case
registry or lack of metabolic abnormalities.
Islet autoantibody frequency in slow progressors
differs between study cohorts
The most frequent autoantibodies in the first mAab-positive
samples were GADA (92%), followed by ZnT8A (62%), IAA
(59%) and IA-2A (41%) (Fig. 1a–d). Of 117 individuals tested
for all four antibodies (Table 2), nine (8%) had four antibod-
ies, with the most common combination of three antibodies
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Fig. 1 Proportion of slow
progressors positive for (a) IAA,
(b) GADA, (c) IA-2A and (d)
ZnT8A at the first available
mAab-positive sample differed
between the cohorts (p=0.001,
p=0.018, p=0.007 and p=0.183,
for each antibody, respectively).
Black bars show overall
percentage, white bars show
percentage for slow progressors
from each study. The ABIS
participants were not tested for
ZnT8A in their first mAab-
positive sample
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being GADA+IA-2A+ZnT8A (in 22 individuals, 19%) and of
two antibodies being IAA+GADA (in 31 individuals, 26%).
The frequency of IAA, GADA and IA-2A, but not ZnT8A,
differed between cohorts (p = 0.001, p = 0.018, p = 0.007 and
p = 0.183, respectively, Fig. 1). In ABIS, of ten slow
progressors tested at age 11 years for ZnT8A, five were
positive.
Slow progressors carry less HLA risk than individuals
diagnosed in childhood
High risk HLA class II (DQ2/DQ8) was less frequent (28% vs
42%) while intermediate risk genotypes were more common
(55% vs 49%) in the 121 slow progressors with HLA class II
data available, than in the 348 children from BOX diagnosed
under 5 years of age, who were designated rapid progressors
(p = 0.011, Fig. 2a). Genetic risk of the slow progressors was
similar to that of the 1217 BOX participants diagnosed over
10 years of age (DQ2/DQ8, 26%). A similar proportion, two
of 121 (1.7%) slow progressors, carried the protective
DQB1*0602 allele compared with six (1.7%) rapid
progressors. HLA class II genetic risk varied between cohorts,
but the frequency of DQ2 and DQ8 alleles was not signifi-
cantly different (Fig. 2b).
Discussion
Here we describe a unique group of 132 slow progressors with
mAab positivity who remained diabetes-free for at least
10 years while participating in five international natural histo-
ry studies. Most remained diabetes-free at last contact but
could be expected to develop diabetes in the future. Indeed,
32% developed diabetes during 4 years of SNAIL follow-up.
Diabetes diagnosis was self-reported for the BOX and
Pittsburgh studies. This analysis brought together data from
several well-characterised long running studies which will en-
able further analysis of these rare individuals. Most study par-
ticipants were first-degree relatives of people with type 1 dia-
betes but also included individuals selected for HLA risk and
from the general population.
All five ‘parent’ studies are longitudinal in nature; serum
samples were collected and assayed over decades. Slow
progressors were initially identified from historic antibody
assay screening results. To allow comparison of data, where
possible, the initial antibody-positive sample and/or subse-
quent samples were retested using standardised assays to con-
firm autoantibody status and these results are reported here.
The definition of slow progressor was the same for all
cohorts included in this analysis, although the parent studies
had different structures. The BOX and Pittsburgh family stud-
ies recruited relatives of individuals with diabetes at different
ages and the age of seroconversion is often unknown. In con-
trast, BABYDIAB, ABIS and most DAISY participants have
been studied from birth and provide valuable evidence that
even individuals who develop antibodies early in life can re-
main diabetes-free for many years. Diabetes was defined by
clinical disease, but metabolic abnormalities may appear be-
fore overt disease. All participants from BABYDIAB were
normoglycaemic, while 1 of 10 DAISY participants tested,
and 3 of 11 BOX participants tested recently, have elevated
HbA1c. In BABYDIAB the slow progressors described here
Age at diagnosis (years) 
Under 5 5–9 10–14 15–20 SPs
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Fig. 2 HLA risks for (a) proportion of HLA class II high risk (black),
intermediate risk (grey) or low risk (white) genotypes in BOX probands
according to age at diagnosis (n=2075, including 348 rapid progressors
diagnosed under 5 years of age) and slow progressors (SPs, n=121,
p=0.011 for HLA class II risk in slow vs rapid progressors); and (b)
proportion of participants carrying HLA class II DQ2 (white) or DQ8
(black) haplotypes in BOX (n=36), BABYDIAB (n=22), DAISY
(n=30), Pittsburgh study (n=21) and ABIS (n=10)
Table 2 Combinations of autoantibodies at first mAab-positive visit
for 117 slow progressors tested for IAA, GADA, IA-2A and ZnT8A
Autoantibody combination Number of individuals (%)
IAA+GADA+IA-2A+ZnT8A 9 (8)
IAA+GADA+IA-2A 6 (5)
IAA+GADA+ZnT8A 11 (9)
IAA+IA-2A+ZnT8A 2 (2)
GADA+IA-2A+ZnT8A 22 (19)
IAA+GADA 31 (26)
IAA+IA-2A 0
IAA+ZnT8A 6 (5)
GADA+IA-2A 8 (7)
GADA+ZnT8A 20 (17)
IA-2A+ZnT8A 2 (2)
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represent 25% of the children who became mAab-positive in
the study [24]. Together these cohorts cover all stages in the
natural history of islet autoimmunity; however, individuals
with a family history of disease are better represented. The
only cohorts included that are representative of the general
population are the ABIS study where individuals with no fam-
ily history were recruited and DAISY where some were re-
cruited from the general population after genetic screening.
All SNAIL participants had mAabs, but the proportion of
individuals with each autoantibody varied between study co-
horts. The first antibodies to be detected in about two-thirds of
young children in BABYDIAB were IAA and their loss was
associated with delayed progression [25]. In the SNAIL co-
horts, IAA were more common in the first mAab-positive
samples from BABYDIAB and ABIS children, but half of
BOX and Pittsburgh family study participants were also
IAA-positive in their first sample, despite most being tested
first as adults. Autoantibodies to GAD are the first islet auto-
antibody detected in about a third of children who develop
diabetes but are also prevalent in adult onset disease [21,
26]. In SNAIL participants, GADA were common in all co-
horts but more frequent in older individuals. Antibodies that
recognise IA-2 and ZnT8 develop later in disease pathogene-
sis and are associated with progression [11]; however, ZnT8A
were the second most frequent antibodies found in slow
progressors. In contrast, IA-2A were less common and
BABYDIAB participants had a particularly low prevalence
of IA-2A (14%). During follow-up, however, 18 of 22
(82%) BABYDIAB SNAIL participants seroconverted to
IA-2A positivity, indicating that antigen spreading continued
despite slower progression (data not shown).
The slow progressors in SNAIL have a lower prevalence
of DQ2/DQ8 compared with well-characterised rapid
progressors diagnosed under the age of five from BOX
but a similar genetic risk profile to individuals diagnosed
in adolescence. In contrast, BABYDIAB showed that chil-
dren who develop islet autoantibodies early in life have
similar high HLA class II risk, independent of whether they
progress to diabetes [24]. One reason for this discrepancy
may be that the average age of detection of islet autoanti-
bodies in SNAIL participants was during adolescence.
Later development of autoantibodies is associated with low-
er HLA class II risk as these genes are known to influence
antibody development, whereas HLA class I genes have a
more dominant role in progression from autoimmunity to
disease [7, 8]. The frequency of DQ2 and DQ8 did not
differ between cohorts despite differences in participant
age between the studies, but this may have been due to a
lack of statistical power for comparisons between cohorts.
The different structures, ages or ethnicities of the SNAIL
cohorts should be considered in interpretation of our analy-
ses. HLA class II risk in children diagnosed under 5 years
old is likely to be similar in Western populations, i.e. 36–
42% have the highest HLA risk in the type 1 diabetes
genetics consortium, DAISY and BOX studies [27]. In ad-
dition, over 95% of participants in BABYDIAB, ABIS,
BOX and Pittsburgh were of white European origin. For
older participants, the age of multiple antibody seroconver-
sion is not known, limiting the interpretation of HLA class
II data. Those who seroconverted at a younger age however
appear to have similar HLA class II regardless of future
progression rate.
On the basis of their mAab positivity, slow progressors
are at high risk of developing type 1 diabetes. Despite hav-
ing a lower genetic risk of disease than rapid progressors,
almost 30% of slow progressors carry the highest HLA class
II risk haplotype, highlighting the importance of other fac-
tors in influencing progression to clinical disease. Continued
study of SNAIL participants will focus on characteristics of
the immune response, including antibody characteristics, and
investigate whether these individuals develop the disease
slowly or not at all because of immune regulation.
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